AOA Dx Secures $20 Million in Funding to Revolutionize Early-Stage Cancer Detection for Women

AOA Dx, a groundbreaking biotechnology company dedicated to advancing early-stage cancer detection specifically for women, is thrilled to announce the successful closing of a $20 million oversubscribed Seed Round. This funding, supported by prestigious backers including Y Combinator and other venture capital firms, will significantly accelerate AOA Dx's ambitious research and development efforts, particularly in clinical studies aimed at refining their pioneering GlycoLocate™ tumor marker platform. AOA Dx is particularly focused on unveiling its flagship product, AKRIVIS GD™, an innovative liquid biopsy test for ovarian cancer that has showcased remarkable sensitivity and specificity in preliminary studies. By harnessing the potential of glycolipids and proprietary biomarker technology, AOA Dx aims to redefine the future landscape of cancer diagnostics, prognosis, and targeted therapies across various cancer types. Co-founded by a trio of women’s health advocates with a successful track record in diagnostics, each armed with deep expertise from previous startups that achieved successful exits, AOA Dx is well-positioned to revolutionize the way cancers are detected and treated. In recognition of its transformative potential, AOA Dx has garnered several awards, including the Massachusetts Life Sciences Center MassNextGen Award and the Inc. Magazine Top 100 Female Founders accolade. As AOA Dx prepares to revolutionize early cancer detection and treatment, this funding marks a significant step forward in their mission to enhance women’s health globally. For more information about AOA Dx and its innovative solutions, visit www.aoadx.com.